[8-K] La Rosa Holding Corp. Reports Material Event

Rhea-AI Filing Summary

Silexion Therapeutics Corp (SLXN) has filed an amended Form 8-K to clarify timing details surrounding its Nasdaq listing status.

The Nasdaq hearings panel has granted the company continued listing but will transfer the ordinary shares and warrants from the Nasdaq Global Market to the Nasdaq Capital Market as soon as practicable. While the original filing stated the move could occur on 8 July 2025, the amendment notes the exact date remains uncertain.

Silexion also warns it may become non-compliant with Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price) if its shares close below that threshold for 30 straight trading days. Management intends to cure any deficiency through a 1-for-15 reverse share split, subject to shareholder approval at the reconvened AGM on 14 July 2025. After approval, a mandatory 10-day Nasdaq notice period would push the split to roughly 25 July 2025, with compliance only achieved after the stock trades above $1.00 for 10 consecutive days—placing the earliest compliance window in early-to-mid August 2025.

The company cautions that there is no assurance shareholders will approve the split or that the post-split price will meet Nasdaq requirements, leaving a continued risk of delisting.

Positive

• Nasdaq hearings panel allowed continued listing, giving SLXN time to address deficiencies.
• Clear, time-bound compliance plan (1-for-15 reverse split followed by 10-day trading window) provides visibility to investors.

Negative

• Downgrade from Nasdaq Global Market to Nasdaq Capital Market signals higher risk and lower listing standards.
• Potential bid-price deficiency remains unresolved; success depends on shareholder approval and post-split market performance.
• Reverse split ratio of 1-for-15 could reduce liquidity and negatively impact existing shareholders.

Insights

Sell-Side Financial Analyst

TL;DR: Listing preserved but downgraded; compliance hinges on reverse split and share performance.

The hearing outcome averts immediate delisting, preserving access to U.S. capital markets, yet the move to the Nasdaq Capital Market signals elevated risk. A 1-for-15 reverse split typically reduces float and may improve bid price optics but does not address underlying valuation drivers; sustained post-split trading above $1 is uncertain without catalysts. Investors should watch the 14 July AGM vote and volume/liquidity after the anticipated 25 July split. Given the absence of financial metrics or operational updates, I view the disclosure as neutral for valuation but highlighting near-term technical overhang.

Corporate Governance & Listing Compliance Expert

TL;DR: Downgrade to Capital Market and reliance on shareholder-approved split heighten governance and compliance risk.

Transferring to the Nasdaq Capital Market reduces minimum listing standards, reflecting the company’s weakened compliance profile. The reliance on a reverse split approved by shareholders within six days is tight; failure would likely trigger a definitive delisting path. Even if approved, the market must accept the higher per-share price for 10 sessions—no guarantee in a micro-cap biotech with limited liquidity. Therefore, I classify the situation as carrying a negative governance signal, though not yet terminal.

--12-31 false 0001879403 0001879403 2025-07-02 2025-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 2, 2025

LA ROSA HOLDINGS CORP.

(Exact name of registrant as specified in its charter)

Nevada		001-41588		87-1641189
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification No.)

1420 Celebration Blvd., 2nd Floor
Celebration, Florida		34747
(Address of principal executive offices)		(Zip Code)

(321) 250-1799

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		LRHC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.03 Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (this “Current Report”) is incorporated herein by reference.

Item 5.03  Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 2, 2025, La Rosa Holdings Corp., a Nevada corporation (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Articles of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of Nevada to effect an 1-for-80 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), issued and outstanding, effective as of 12:01 a.m. (New York time) on July 7, 2025, (the “Reverse Stock Split”). As previously reported by the Company, on February 4, 2025, the Company’s majority stockholders by a written consent (the “Stockholders Approval”) approved the amendment to the Company’s Amended and Restated Articles of Incorporation, as amended (the “Articles of Incorporation”), to effect a reverse stock split of the Company’s Common Stock at a ratio in the range of 1-for-20 to 1-for-100, with such ratio to be determined by the Company’s board of directors (the “Board”). Such resolution of the majority stockholders became effected on March 28, 2025, or twenty (20) days after the Company filed with the Securities Commission (the “SEC”) and mailed to its stockholders respective Information Statement on Schedule 14C on or approximately March 7, 2025. Following the Stockholders Approval, the Board determined to effect the Reverse Stock Split at a ratio of 1-for-80 and approved the corresponding final form of the Certificate of Amendment.

As a result of the Reverse Stock Split, every eighty (80) shares of issued and outstanding Common Stock were automatically combined into one (1) issued and outstanding share of Common Stock. No fractional shares were issued as a result of the Reverse Stock Split, fractional entitlements were rounded up to the next whole number. The Reverse Stock Split reduced the number of shares of Common Stock outstanding from 58,317,932 shares to 729,039 shares. The number of authorized shares of Common Stock under the Articles of Incorporation remained unchanged at 2 billion 50 million (2,050,000,000) shares and the par value of the Common Stock remained $0.0001 per share.

The Common Stock began trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on July 7, 2025. The trading symbol for the Common Stock remained “LRHC.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 50172T202.

Proportionate adjustments were also made to the per share exercise price and the number of shares of Common Stock that may be purchased upon exercise of outstanding stock options granted by the Company, and the number of shares of Common Stock reserved for future issuance under the Company’s equity incentive plans. The Company adjusted the number of shares available for issuance upon the exercise of outstanding warrants to issue Common Stock as well as the exercise price to reflect the effects of the Reverse Stock Split. The Company also adjusted the number of shares issuable upon conversion of outstanding restricted stock units to reflect the effects of the Reverse Stock Split.

The information set forth herein is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report and is incorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

On July 2, 2025, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

1

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
3.1		Certificate of Amendment to Amended and Restated Articles of Incorporation of La Rosa Holdings Corp., filed on July 2, 2025
99.1		Press release of the Company issued on July 2, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 8, 2025	LA ROSA HOLDINGS CORP.
	By:	/s/ Joseph La Rosa
	Name:	Joseph La Rosa
	Title:	Chief Executive Officer

3

FAQ

Why is Silexion Therapeutics (SLXN) moving to the Nasdaq Capital Market?

The hearings panel granted continued listing but required a transfer to the Capital Market due to compliance concerns.

When will the 1-for-15 reverse stock split for SLXN occur?

If shareholders approve on 14 July 2025, the split could be effected after a 10-day notice period, around 25 July 2025.

How will SLXN regain compliance with the $1.00 minimum bid rule?

Post-split, the stock must close above $1.00 for 10 consecutive trading days, likely in early-to-mid August 2025.

What happens if SLXN shareholders reject the reverse split proposal?

Failure to approve would leave the company without a clear path to cure the bid-price deficiency, increasing delisting risk.

Does the amendment affect any other information from the original 8-K?

No. It solely updates timing for the market transfer and potential bid-price compliance schedule.